Foghorn Therapeutics Inc.

NasdaqGM:FHTX 株式レポート

時価総額：US$517.9m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Foghorn Therapeutics マネジメント

マネジメント 基準チェック /34

Foghorn Therapeutics'の CEO はAdrian H. Gottschalkで、 May2017年に任命され、 の在任期間は 7.08年です。 の年間総報酬は$ 2.50Mで、 23.1%給与と76.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.92%を直接所有しており、その価値は$ 2.87M 。経営陣と取締役会の平均在任期間はそれぞれ2.4年と6.9年です。

主要情報

Adrian H. Gottschalk

最高経営責任者

US$2.5m

報酬総額

CEO給与比率23.1%
CEO在任期間7.3yrs
CEOの所有権0.9%
経営陣の平均在職期間less than a year
取締役会の平均在任期間7.2yrs

経営陣の近況

Recent updates

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up

Sep 01
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up

Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking

Jul 17
Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

May 09
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth

Apr 12
Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too

Feb 22
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth

Dec 13
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth

Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues

Nov 07
Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues

Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans

Jun 14
Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans

Foghorn Therapeutics: Selling For Less Than Cash Value

Oct 10

Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286

Aug 23

Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M

Aug 09

Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity

Jun 02

We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely

Apr 13
We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely

Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?

Feb 27
Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?

CEO報酬分析

Foghorn Therapeutics の収益と比較して、Adrian H. Gottschalk の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

-US$86m

Mar 31 2024n/an/a

-US$93m

Dec 31 2023US$3mUS$579k

-US$98m

Sep 30 2023n/an/a

-US$103m

Jun 30 2023n/an/a

-US$115m

Mar 31 2023n/an/a

-US$112m

Dec 31 2022US$5mUS$575k

-US$109m

Sep 30 2022n/an/a

-US$109m

Jun 30 2022n/an/a

-US$109m

Mar 31 2022n/an/a

-US$105m

Dec 31 2021US$4mUS$540k

-US$101m

Sep 30 2021n/an/a

-US$93m

Jun 30 2021n/an/a

-US$85m

Mar 31 2021n/an/a

-US$78m

Dec 31 2020US$3mUS$479k

-US$69m

Sep 30 2020n/an/a

-US$63m

Jun 30 2020n/an/a

-US$58m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$1mUS$465k

-US$51m

報酬と市場: Adrian H.の 総報酬 ($USD 2.50M ) は、 US市場 ($USD 2.48M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Adrian H.の報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Adrian H. Gottschalk (48 yo)

7.3yrs

在職期間

US$2,503,942

報酬

Mr. Adrian H. B. Gottschalk serves as President, Chief Executive Officer and a Director of Foghorn Therapeutics Inc. since May, 2017. Prior to joining Foghorn and since 2004, Mr. Gottschalk worked at Bioge...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Adrian H. Gottschalk
President7.3yrsUS$2.50m0.92%
$ 4.8m
Steven Bellon
Chief Scientific Officer2.7yrsUS$1.19m0.27%
$ 1.4m
Alfonso Cardama
Chief Medical Officerless than a yearUS$1.84mデータなし
Gerald Crabtree
Founder & Member of Scientific Advisory Boardno dataデータなしデータなし
Kristian Humer
Chief Financial Officerless than a yearデータなしデータなし
Karin Hellsvik
VP of Corporate Affairs & Investor Relationsless than a yearデータなしデータなし
Michael LaCascia
Chief Legal Officer3.8yrsUS$1.99m0%
$ 0
Saurabh Sewak
Vice President of Corporate Development2.7yrsデータなしデータなし
Carlos Costa
Chief People Officerno dataデータなしデータなし
Anna Rivkin
Chief Business Officerno dataデータなしデータなし
Michael Garcia-Webb
VP & Chief of Staff Researchless than a yearデータなしデータなし

1.0yrs

平均在職期間

52yo

平均年齢

経験豊富な経営陣: FHTXの経営陣は 経験豊富 とはみなされません ( 1.8年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称ポジション在職期間報酬所有権
Adrian H. Gottschalk
President7.3yrsUS$2.50m0.92%
$ 4.8m
Gerald Crabtree
Founder & Member of Scientific Advisory Boardno dataデータなしデータなし
B. Parshall
Independent Director2.1yrsUS$157.65k0%
$ 0
Balkrishan Gill
Independent Director7.2yrsUS$159.07k0.062%
$ 318.8k
Douglas Cole
Founder & Independent Chairman of the Board8.9yrsUS$184.57k0%
$ 0
Charles Sawyers
Member of Scientific Advisory Boardno dataデータなしデータなし
David Schenkein
Member of Scientific Advisory Boardno dataデータなしデータなし
Anthony Kouzarides
Member of Scientific Advisory Boardno dataデータなしデータなし
Adam Koppel
Independent Director7.2yrsUS$153.07k0%
$ 0
Michael Mendelsohn
Independent Director7.4yrsUS$154.57k0%
$ 0
Scott Biller
Independent Director4.7yrsUS$145.57k0%
$ 0
Cigall Kadoch
Member of Scientific Advisory Board2yrsUS$252.52k6.55%
$ 33.9m

7.2yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: FHTXの 取締役会 は 経験豊富 であると考えられます ( 6.9年の平均在任期間)。